BORDEAUX, France--(BUSINESS WIRE)--Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders.
Aelis Farma held its combined general meeting of shareholders on May 24, 2023, which was chaired by Mr. Anders Gersel Pedersen, Chairman of the Board of directors.
With a quorum of 85%, the shareholders have adopted all the resolutions recommended by the Board of Directors, in particular the financial statements for the 2022 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board of directors related to financial transactions.
Shareholders also approved the transfer of the registered office at 1 rue Lafaurie de Monbadon - 33000 Bordeaux (France).
Details on the vote results will be available on the Company’s website.
About AELIS FARMA
Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). CB1-SSi have been developed by Aelis Farma based on the discovery of a new natural brain defense mechanism by the team led by Dr. Pier Vincenzo Piazza, the Company’s CEO, when he was Director of the INSERM Magendie Neurocenter in Bordeaux. By reproducing this natural mechanism, CB1-SSi appear to be capable of selectively inhibiting the disease-related activity of the CB1 receptor without disrupting its normal physiological activity. They thus have significant potential for the treatment of numerous brain diseases.
Aelis Farma is developing two first-in-class clinical-stage drug candidates: AEF0117 for the treatment of disorders due to excessive cannabis use, currently in a phase 2b study in the United States; and AEF0217 for cognitive disorders, including those of Down Syndrome (Trisomy 21), currently in a phase 1/2 study in Spain. The Company also has a portfolio of innovative CB1-SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB1 receptor.
Aelis Farma draws on the talents of more than 20 highly qualified employees.
For more information, visit www.aelisfarma.com and follow us on LinkedIn and Twitter.
B Compartment of Euronext Paris
Some information contained in this press release are forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, or achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration Document approved by the Autorité des Marchés Financiers on April 26, 2023, under number R.23-018.
These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.